ArticleScientific reports2025

Cost effectiveness of bevacizumab plus carboplatin paclitaxel versus carboplatin paclitaxel as front line for advanced ovarian cancer in Thailand.

Kanyarat Katanyoo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.